[Comparative safety of traditional non-steroidal anti-inflammatory drugs and COX-2 selective inhibitors].
SIDE EFFECTS OF NON-STEROIDAL ANTI-INFLAMMATORY DRUGS: Digestive disorders and skin and mucosal reactions, more rarely neurosensorial, renovascular, gyneco-obstetrical and hematological disorders are the main side effects of non-steroidal anti-inflammatory drugs. DIGESTIVE USEFULNESS OF COXIBS: Coxibs reduce the risk of symptomatic complicated or uncomplicated gastroduodenal ulcers by 1 to 1.5 per 100 patient-years compared with conventional NSAID. They do however induce a similar number of dyspeptic disorders and are contraindicated in case of inflammatory bowel disease. Extra-digestive tolerance is comparable with that for classical NSAID. PLATELET AGGREGATION AND THROMBOSIS: If the patient's vascular status requires an anti-platelet agent, aspirin must be combined with the coxib which in itself cannot provide cardiovascular protection.
Bannwarth
B
B
Service de rhumatologie Laboratoire de Thérapeutique, Université Victor Segalen, Bordeaux, France.
D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000009:adverse effects* / Q000627:therapeutic use; D001172:Arthritis, Rheumatoid / Q000188:drug therapy*; D051546:Cyclooxygenase 2; D052246:Cyclooxygenase 2 Inhibitors; D016861:Cyclooxygenase Inhibitors / Q000009:adverse effects* / Q000627:therapeutic use; D006801:Humans; D007527:Isoenzymes / Q000037:antagonists & inhibitors*; D008565:Membrane Proteins; D010003:Osteoarthritis / Q000188:drug therapy*; D011451:Prostaglandin-Endoperoxide Synthases; D018570:Risk Assessment
D000894:Anti-Inflammatory Agents, Non-Steroidal; D052246:Cyclooxygenase 2 Inhibitors; D016861:Cyclooxygenase Inhibitors; D007527:Isoenzymes; D008565:Membrane Proteins; D051546:Cyclooxygenase 2; C496540:PTGS2 protein, human; D011451:Prostaglandin-Endoperoxide Synthases